Expressions of some vital molecules: Glioblastoma multiforme versus normal tissues

Neurological Research

Volumn 32, Issue 5, 2010, Pages 492-501

  Atukeren, Pinar ^a   Kemerdere, Rahsan ^a   Kacira, Tibet ^b   Hanimoglu, Hakan ^a   Ozlen, Fatma ^a   Yavuz, Berna ^a   Tanriverdi, Taner ^c   Gumustas, Koray ^a   Canbaz, Bulent ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Pasabahce State Hospital   (Turkey)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Adhesion molecules; Apoptosis; Cytokines; Glioblastoma multiforme; Lipid peroxidation; Myeloperoxidase; Nitric oxide; Superoxide dismutase

Indexed keywords

3 NITROTYROSINE; FAS ANTIGEN; FAS LIGAND; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MYELOPEROXIDASE; NITRATE; NITRITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOPSY; BRAIN REGION; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MALE; PROTEIN EXPRESSION; BLOOD; BLOOD ANALYSIS; BRAIN; BRAIN TUMOR; CASE CONTROL STUDY; CHILD; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; BRAIN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CHILD; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77952863796     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313209X459075     Document Type: Article

References (76)

1. Klehiues P, Burger PC, Collins VP, et al. Pathology and Genetics of Tumors of the Nervous System, Lyon: International Agency for Research on Cancer, 2000: pp. 29-39.
2. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-310.
3. Sun Y, Sun Y, Oberley LW, et al. A simple method for clinical assay of super oxide dismutase. Clin Chem 1998; 34: 497-500.
4. Dedhar S. Integrins and tumor invasion. Bioassays 1990; 12: 583-590.
5. Simmons D, Makgoba MW, Seed B. ICAM-1, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecules NCAM. Nature 1998; 331: 624-627.
6. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59: 1203-1211.
7. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-434.
8. Springer TA, Dustin ML, Kishimoto TK, et al. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: Cell adhesion receptors of the immune system. Annu Rev Immunol 1987; 5: 223-252.
9. Wong D, Dorovini-Zis K. Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of human brain microvessel endothelial cells by cytokines and lipopolysaccharide. J Neuroimmunol 1992; 39: 11-21.
10. Gingras MC, Roussel E, Bruner JM, et al. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 1996; 57: 143-153.
11. Maenpaa A, Kovanen PE, Paetau A, et al. Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain: Expression of VCAM-1 in gliomas. Acta Neuropathol 1997; 94: 216-225.
12. Kaynar MY, Tanriverdi T, Kafadar AM, et al. Detection of soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in both cerebrospinal fluid and serum of patients after aneurismal subarachnoid hemorrhage. J Neurosurg 2004; 101: 1030-1036.
13. Guarini L, Temponi M, Bruce JN, et al. Expression and modulation by cytokines of the Intercellular adhesion molecule-1 (ICAM-1) in human central nervous system tumor cell cultures. Int J Cancer 1990; 46: 1041-1047.
14. Rosenman SJ, Shrikant P, Dubb L, et al. Cytokine-induced expression of vascular cell adhesion molecule-1 (VCAM-1) by astrocytes and astrocytoma cell lines. J Immunol 1995; 154: 1888- 1899.
15. Banks RE, Gearing AJH, Hemingway IK, et al. Circulating intercellular adhesion molecule-1, E selectin and vascular cell adhesion molecule-1 (VCAM) in human malignancies. Br J Cancer 1993; 68: 122-124.
16. Moynagh PN, Williams DC, O'Neill AJ. Activation of NF-kB and induction of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in human glial cells by IL-1. J Immunol 1994; 153: 2681-2688.
17. Vitolo D, Paradiso P, Uccini S, et al. Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: Relation to angiogenesis and spread. Histopathology 1996; 28: 521-528.
18. Salmaggi A, Eoli M, Frigerio S, et al. Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. Cancer Lett 1999; 146: 169-172.
19. Kuppner MC, Hamouu MF, de Tribolet N. Activation and adhesion molecule expression on lymphoid infiltrates in human glioblastomas. J Neuroimmunol 1990; 29: 229-238.
20. Yednock TC, Cannon L, Fritz F, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin. Nature 1992; 356: 63-65.
21. Lee SJ, Drabik LK, Van Wagoner NJ, et al. ICAM-1-induced expression of proinflammatory cytokines in astrocytes: Involvement of extracellular of extracellular signal-regulated kinas and p38 mitogen-activated protein kinase pathways. J Immunol 2000; 165: 4658-4666.
22. Migheli A, Cavalla P, Marino S, et al. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 1994; 53: 606-616.
23. Petak I, Houghton JA. Shared pathways: Death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001; 7: 95-106.
24. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
25. Cappello F, Bellafiore M, Palma A, et al. Defective apoptosis and tumorigenesis: Role of p53 mutation and Fas/FasL system dysregulation. Eur J Histochem 2002; 46: 199-208.
26. Gratas C, Tohma Y, Van Meir EG, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 1997; 7: 863-869.
27. Riffkin CD, Gray AZ, Hawkins CJ, et al. Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. Neuro-oncology 2001; 3: 229-240.
28. Ichinose M, Masuoka J, Shiraishi T, et al. Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors. Brain Tumor Pathol 2001; 18: 37-42.
29. Uzan M, Erman H, Tanriverdi T, et al. Evaluation of apoptosis in cerebrospinal fluid of patients with severe head injury. Acta Neurol (Wien) 2006; 148: 1157-1164.
30. Choi K, Benveniste EN, Choi C. Induction of intercellular adhesion molecule-1 by Fas ligation: Proinflammatory roles of Fas in human astroglioma cells. Neurosci Lett 2003; 352: 21-24.
31. Strege R, Godt C, Stark AM, et al. Protein expression of Fas, Fas ligand, Bcl-2 and TGFb2 and correlation with survival in initial and recurrent human gliomas. J Neurooncol 2004; 67: 29-39.
32. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: Attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188: 97-113.
33. Frankel B, Longo SL, Ryken TC, et al. Human astrocytomas coexpressing Fas and Fas ligand also produce TGFb2 and Bcl-2. J Neurooncol 1999; 44: 205-212.
34. Tachibana C, Tachibana C, Nakazawa H, et al. Expression of Fas/ APO-1 during the progression of astrocytomas. Cancer Res 1995; 55: 5528-5530.
35. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 1996; 2: 1361-1366.
36. Tews DS. Cell death and oxidative stress in gliomas. Neuropathol Appl Neurobiol 1999; 25: 272-284.
37. Chen GG, Chak ECW, Chun YS, et al. Glioma apoptosis induced by macrophages involves both death receptor-dependent and independent pathways. J Lab Clin Med 2003; 141: 190-199.
38. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
39. Szelenyi J. Cytokines and the central nervous system. Brain Res Bull 2001; 54: 329-338.
40. Chen TC, Hinton DR, Apuzzo MLJ, et al. Differential effects of tumor necrosis factor-alpha on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas. Neurosurgery 1993; 32: 85-94.
41. Tada M, Diserens AC, Desbaillets I, et al. Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J Neurosurg 1994; 80: 1063-1073.
42. Chen TC, Hinton DR, Sippy BD, et al. Soluble TNF-a receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas. J Neuropathol Exp Neurol 1997; 56: 541-550.
43. Cuny E, Loiseau H, Pecnet G, et al. Association of elevated glial expression of interleukin-1b with improved survival in patients with glioblastoma multiforme. J Neurosurg 2002; 96: 294-301.
44. Dunger A, Augstein P, Schmidt S, et al. Identification of interleukin 1-induced apoptosis in rat islets using in situ specific labelling of fragmented DNA. J Autoimmun 1996; 9: 309-313.
45. Sharma V,Mishra M, Ghosh S, et al. Modulation of interleukin-1b mediated inflammatory response in human astrocytes by flavonoids: Implications in neuroprotection. Brain Res Bull 2007; 73: 55-63.
46. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: Helpful and harmful. Trends Neurosci 1996; 19: 331-338.
47. Yun HY, Dawson VL, Dawson TM. Nitric oxide in health and disease of the nervous system. Mol Psychiatry 1997; 2: 300-310.
48. Zisakis A, Piperi C, Themistocleous MS, et al. Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine 2007; 39: 99-105.
49. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical produced by peroxynitrite: Implications of endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-1624.
50. Banks BA, Ischiropoulos H, McClelland M, et al. Plasma 3- nitrotyrosine is elevated in premature infants who develop bronchopulmonary dysplasia. Pediatrics 1998; 101: 870-874.
51. Shishehbor MH, Ronnier DO, Aviles J, et al. Levels of nitrotyrosine, an inflammatory marker generated by nitric oxide derived oxidants, is both associated with risk of coronary artery disease and modulated by statin therapy, JAMA 2003; 289: 1675-1680.
52. Estevez AG, Spear N, Manuel SM, et al. Nitric oxide and superoxide contribute to motor neuron apoptosis induced by trophic factor deprivation. J Neurosci 1998; 18: 923-931.
53. Fiore G, Di Cristo C, Monti G, et al. Tubulin nitration in human gliomas. Neurosci Lett 2006; 394: 57-62.
54. Uzan M, Tanriover N, Topal-Sarikaya A, et al. Concentrations of inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS) in cerebrospinal fluid of patients with severe head injury. Neurosurg Q 2003; 13: 117-124.
55. Tuzgen, Tanriover N, Uzan M, et al. Nitric oxide levels in rat cortex, hippocampus, cerebellum, and brainstem after impact acceleration injury. Neurol Res 2003; 25: 31-34.
56. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-695.
57. Wink DA, Kasprzak KS, Maragos CM, et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991; 254: 1001-1003.
58. Chin K, Kurashima Y, Ogura T, et al. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene 1997; 15: 437-442.
59. Kato S, Esumi H, Hirano A, et al. Immunohistochemical expression of inducible nitric oxide synthase (iNOS) in human brain tumors: Relationships of iNOS to superoxide dismutase (SOD) proteins (SOD1 and SOD2), ki-67 antigen (MIB-1) and p53 protein. Acta Neuropathol 2003; 105: 333-340.
60. Kaynar MY, Sanus GZ, Hanimoglu H, et al. Expression of hypoxia inducible factor-1a in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci 2008; 15: 1036-1042.
61. Hanimoglu H, Tanriverdi T, Kacira T, et al. Relationship between DNA damage and total antioxidant capacity in patients with transitional meningioma. Clin Neurol Neurosurg 2007; 109: 561-566. (Pubitemid 47016754)
62. Tanriverdi T, Hanimoglu H, Kacira T, et al. Glutathione peroxidise, glutathione reductase and protein oxidation in patients with glioblastoma multiforme and transitional meningioma. J Cancer Res Clin Oncol 2007; 133: 627-633.
63. Tuzgen S, Hanimoglu H, Tanriverdi T, et al. Relationship between DNA damage and total antioxidant capacity in patients with glioblastoma multiforme. Clin Oncol (R Coll Radiol) 2007; 19: 177-181.
64. Gumustas K, Tanriverdi T, Kulaksiz I, et al. Cytochrome oxidase activity and ATP levels in high-grade gliomas and meningiomas. Turk Neurosurg 2006; 16: 64-68.
65. Rao GM, Rao AV, Raja A, et al. Lipid peroxidation in brain tumors. Clin Chim Acta 2000; 302: 205-211.
66. Zengin E, Atukeren P, Kokoglu E, et al. Alterations in lipid peroxidation and antioxidant status in different types of intracranial tumors within their relative peritumoral tissues. Clin Neurol Neurosurg 2009; 111: 345-351.
67. Weil SC, Rosner GL, Reid MS, et al. cDNA cloning of human myeloperoxidase: Decrease in myeloperoxidase mRNA upon induction of HL-60 cells. Proc Natl Acad Sci USA 1987; 84: 2057-2061.
68. Maki RA, Tyurin VA, Lyon RC, et al. Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of alzheimer's disease. J Biol Chem 2009; 284: 3158-3169.
69. Cascorbi I, Henning S, Brockmoller, J et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant- 463A of the myeloperoxidase gene. Cancer Res 2000; 60: 644-649.
70. Pakakasama S, Chen TT, Frawley W, et al. Myeloperoxidase promotor polymorphism and risk of hepatoblastoma. Int J Cancer 2003; 106: 205-207.
71. Tsuruta Y, Subrahmanyam VV, Marshall W, et al. Peroxidasemediated irreversible binding of arylamine carcinogens to DNA in intact polymorphonuclear leukocytes activated by a tumor promoter. Chem Biol Interact 1985; 53: 25-35.
72. Henderson JP, Byun J, Takeshita J, et al. Phagocytes produce 5- chlorouracil and 5-bromouracil, two mutagenic products of myeloperoxidase, in human inflammatory tissue. J Biol Chem 2003; 278: 23522-23528.
73. Levchenko LI, Demchuk ML. Lipid peroxidation and antioxidative activity in the tumor tissue and blood of patients with neurological disease. Zh Vopr Neirokher Im NN Burdenko 1991; 4: 23-25.
74. Pu PY, Lan J, Shan SB, et al. Study of the antioxidant enzymes in human brain tumors. J Neurooncol 1996; 29: 121-128.
75. Del Maestro R, Warren M, Robert A. SOD, catalase and glutathione peroxidase in experimental and human brain tumors. In: Robert AG, Gohen G, eds. Oxyradicals and their Scavenger Systems, Vol.II, Cellular and Medical Aspects, New York: Elsevier Science, 1983: pp. 28-36.
76. Rao GM, Rao AV, Raja A, et al. Role of antioxidant enzymes in brain tumors. Clin Chim Acta 2000; 296: 203-212.